Psyence Biomedical Files 6-K Detailing Securities Agreements
Ticker: PBMWW · Form: 6-K · Filed: Dec 31, 2024 · CIK: 1985062
Sentiment: neutral
Topics: securities, financing, warrants, agreements
TL;DR
Psyence Biomedical inked new warrant and purchase deals on Dec 23rd, filing the details today.
AI Summary
Psyence Biomedical Ltd. filed a Form 6-K on December 31, 2024, reporting on events for the month of December 2024. The filing includes several exhibits related to securities, such as forms of pre-funded warrants, Series A warrants, Series B warrants, and placement agent warrants. It also details a Securities Purchase Agreement dated December 23, 2024, and a related Registration Rights Agreement.
Why It Matters
This filing provides insight into Psyence Biomedical's recent financing activities and the terms of warrants and purchase agreements, which could impact its capital structure and future share dilution.
Risk Assessment
Risk Level: medium — The filing concerns securities issuance and purchase agreements, which can introduce dilution and financial risk for existing shareholders.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Filer of the 6-K report and party to the agreements.
- December 23, 2024 (date) — Date of the Securities Purchase Agreement and Registration Rights Agreement.
- 20241231 (date) — Filing date and period of report.
FAQ
What is the purpose of the Securities Purchase Agreement dated December 23, 2024?
The filing indicates a Securities Purchase Agreement was entered into on December 23, 2024, but does not detail its specific purpose beyond the context of securities issuance.
What types of warrants are detailed in the exhibit index?
The exhibit index lists forms for Pre-Funded Warrants, Series A Warrants, Series B Warrants, and Placement Agent Warrants.
When was this Form 6-K filed?
This Form 6-K was filed on December 31, 2024.
What is Psyence Biomedical Ltd.'s principal executive office address?
Psyence Biomedical Ltd.'s principal executive office is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or Form 40-F?
The filing indicates Psyence Biomedical Ltd. files annual reports under Form 20-F.
Filing Stats: 228 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2024-12-31 16:01:54
Filing Documents
- tm2431883d2_6k.htm (6-K) — 12KB
- tm2431883d2_ex4-1.htm (EX-4.1) — 99KB
- tm2431883d2_ex4-2.htm (EX-4.2) — 105KB
- tm2431883d2_ex4-3.htm (EX-4.3) — 104KB
- tm2431883d2_ex4-4.htm (EX-4.4) — 106KB
- tm2431883d2_ex10-1.htm (EX-10.1) — 282KB
- tm2431883d2_ex10-2.htm (EX-10.2) — 142KB
- tm2431883d2_ex99-1.htm (EX-99.1) — 9KB
- tm2431883d2_ex99-2.htm (EX-99.2) — 12KB
- logo.jpg (GRAPHIC) — 8KB
- 0001104659-24-132846.txt ( ) — 885KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX EXHIBIT INDEX Exhibit Description 4.1 Form of Pre-Funded Warrant 4.2 Form of Series A Warrant 4.3 Form of Series B Warrant 4.4 Form of Placement Agent Warrant 10.1 Form of Securities Purchase Agreement, dated December 23, 2024, by and among Psyence Biomedical Ltd. and the Purchasers named therein 10.2 Form of Registration Rights Agreement, dated December 23, 2024, by and among Psyence Biomedical Ltd. and the Holders named therein 99.1 Press Release, dated December 23, 2024 99.2 Press Release, dated December 27, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 31, 2024 Psyence Biomedical Ltd. By: /s/ Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director